General reviews
NEW SYSTEMIC THERAPIES IN THE TREATMENT OF MODERATE TO SEVERE ADULT PLAQUE PSORIASIS

Moderate to severe plaque psoriasis is in the spotlight of large pharmaceutical laboratories that propose dermatologists around the world new increasingly effective drugs, launched at a sustained pace. This article briefly presents the clinical trials that allowed the approval of the new molecules authorized in France and most European Community countries in the last 12 months: anti-interleukin 17A (IL-17A) secukinumab and ixekizumab and anti-phosphodiesterase-4 (PDE-4) apremilast - the first new oral treatment approved. The educational objectives of this article are: 1. a synthetic update to inform dermatologists about the efficacy and tolerance profile of the 3 new drugs against moderate to severe psoriasis in case of therapeutic failure or contraindication to 2 classical treatments; 2. to provide dermatologists with simplified information to prescribe a new systemic therapy well adapted to the profile of each patient with moderately to severe plaque psoriasis.